To characterize the resident and infiltrating immune cell landscape in NSCLC in situ, a workflow was established and optimized for mIHC to assess five different markers to simultaneously depict CD8+ T cells, FOXP3+ Treg cells, PD-1+ cells, and PD-L1+ cells. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.